Human immunodeficiency virus-infected subjects have no altered myocardial perfusion

International Journal of Cardiology

Volumn 122, Issue 1, 2007, Pages 90-92

  Catzin Kuhlmann, Andres ^a   Orea Tejeda, Arturo ^a   Castillo Martínez, Lilia ^a   Colín Ramírez, Eloisa ^a   Asz, Daniel ^a   Aguirre, Víctor H ^a   Herrera, Luis E ^a   Valles, Victoria ^a   Aguilar Salinas, Carlos A ^a   Sierra, Juan ^a   Calva, Juan J ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Antiretroviral therapy; Coronary disease; Emission computed; Human immunodeficiency virus; Single photon; Tomography

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HAZARD; HEART MUSCLE PERFUSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MEXICO; PRIORITY JOURNAL; RISK FACTOR; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; CASE-CONTROL STUDIES; CORONARY CIRCULATION; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34848908384     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.11.040     Document Type: Article

References (9)

1. Barbaro G., Di Lorenzo G., Cirelli A., et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 25 (2003) 2405-2418
2. Bozzette S.A., Ake C.F., Tam H.K., Chang S.W., and Louis T.A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348 (2003) 702-710
3. Currier J.S., Taylor A., Boyd F., et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 33 (2003) 506-512
4. Holmberg S.D., Moorman A.C., Williamson J.M., et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360 (2002) 1747-1748
5. Klein D., Hurley L.B., Quesenberry C.P., and Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?. J Acquir Immune Defic Syndr 30 (2002) 471-477
6. Mary-Krause M., Cotte L., Simon A., Partisani M., Costogliola D., and and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17 (2003) 2479-2486
7. Talwani R., Falusi O.M., Mendes de Leon C.F., et al. Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J Acquir Immune Defic Syndr 30 (2002) 191-195
8. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
9. American Society of Nuclear Cardiology. Updated imaging guidelines for nuclear cardiology procedures, part 1. J Nucl Cardiol 8 1 (Jan-Feb 2001) G5-G58